Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Mimedx (MDXG) Cash from Operations (2016 - 2026)

Mimedx's Cash from Operations history spans 16 years, with the latest figure at 1879000.0 for Q1 2026.

On a quarterly basis, Cash from Operations fell 64.54% to 1879000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was 70583000.0, a 6.22% increase, with the full-year FY2025 number at 74003000.0, up 10.24% from a year prior.
Cash from Operations hit 1879000.0 in Q1 2026 for Mimedx, down from 24956000.0 in the prior quarter.
Over the last five years, Cash from Operations for MDXG hit a ceiling of 29329000.0 in Q3 2025 and a floor of 10223000.0 in Q1 2022.
Historically, Cash from Operations has averaged 9518411.76 across 5 years, with a median of 7775000.0 in 2023.
Biggest five-year swings in Cash from Operations: crashed 287.93% in 2022 and later soared 1233.79% in 2023.
Tracing MDXG's Cash from Operations over 5 years: stood at 4297000.0 in 2022, then soared by 138.7% to 10257000.0 in 2023, then surged by 92.18% to 19712000.0 in 2024, then rose by 26.6% to 24956000.0 in 2025, then tumbled by 92.47% to 1879000.0 in 2026.
Business Quant data shows Cash from Operations for MDXG at 1879000.0 in Q1 2026, 24956000.0 in Q4 2025, and 29329000.0 in Q3 2025.